The adjuvant effects of liver-derived CRCL, HSP70, or LPS in enhancing the immunogenicity of AP2087-induced apoptotic 12B1-D1 cells.

12B1-D1 cells were treated with 40 nM AP20187 for 6 hours. (A) Liver-derived CRCL (20 μg/mouse) or HSP70 was added to the cells and the mixture was injected subcutaneously into the groin of BALB/c mice. Control mice were injected with AP20187-treated cells only. (Control versus HSP70 P < .05 from day 16 onward; control versus CRCL P < .05 from day 15 onward in onward; HSP70 versus CRCL P < .05 from day 17 onward; n = 8 mice per group. Representative data from 1 of 2 experiments are shown.) (B) Liver-derived CRCL (20 μg/mouse) or 10 μg/mouse LPS was added to the cells and the mixture was injected subcutaneously into the groin of BALB/c mice. Control mice were injected with AP20187-treated cells only. (Control versus CRCL P < .05 from day 13 onward; control versus LPS P < .05 from day 13 onward; n = 8 mice per group. Representative data from 1 of 3 experiments are shown.) 12B1-D1/AP indicates 12B1-D1 cells treated with AP20187. Error bars indicate SEM.